ARS Pharmaceuticals, Inc.

Stage 4 · Declining · week 14

As of Oct 22, 2026, ARS Pharmaceuticals is in Stage 4, the downtrend phase, now in week 14 (since Jul 21, 2026). It closed at $4.32, 66.9% below its 52-week high and below its 200-day average, which is falling.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. More about the company

$4.32

+3.35% today

$430M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SPRY early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 17w

S2 22w

S2 16w

S4 14w

S4 13w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 2w → S1 4w → S4 12w → S1 8w → S2 17w → S3 4w → S2 22w → S3 10w → S4 4w → S1 7w → S2 16w → S3 4w → S4 13w → S1 9w → S4 14w → S1 6w → S4 13w current

Total tracked: 166 weeks across 17 stage runs.

SPRY among Biotechnology382nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…382	SPRYARS Pharmaceuticals, Inc.	Stage 4 · wk 14	20	+3.3%

vs 52W High

-66.9%

$3.93 lo$13.06 hi

66.9% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 14

1w13w26w

Week 14, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-43.4%

200 DMA: $7.63 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.12x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+3.3%

-27.3%

-48.0%

YTD

-62.4%

-56.4%

Scan Membership

Breakout Watch

Latest: 2025-05-13

5 appearances in last 60 days. First seen: 2022-08-26.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 14 · Vol 1.12x

2026-10-21S4

Wk 14 · Vol 0.54x

2026-10-20S4

Wk 13 · Vol 0.96x

2026-10-19S4

Wk 13 · Vol 0.93x

2026-10-16S4

Wk 13 · Vol 1.46x

2026-10-15S4

Wk 13 · Vol 1.38x

2026-10-14S4

Wk 13 · Vol 1.07x

2026-10-13S4

Wk 12 · Vol 0.95x

2026-10-12S4

Wk 12 · Vol 0.78x

2026-10-09S4

Wk 12 · Vol 0.77x

2026-10-08S4

Wk 12 · Vol 0.91x

2026-10-07S4

Wk 12 · Vol 0.74x

Moving averages & range

50 DMA

$4.85

200 DMA

$7.63

52W High

$13.06

52W Low

$3.93

5D Low

$4.02

Resistance levels (recent highs)

20d High

$4.56

60d High

$6.38

120d High

$10.54

250d High

$13.06

Next resistance

+5.6%

to 20d High

ROE

-210.3%

Profit margin -184.2%

Dividend Yield

0.00%

P/B 34.3

ARS Pharmaceuticals: quick answers

What stage is ARS Pharmaceuticals in?

As of Oct 22, 2026, ARS Pharmaceuticals (SPRY) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 21, 2026 and is in week 14. What the four stages mean

Is ARS Pharmaceuticals in an uptrend?

No. ARS Pharmaceuticals is in a Stage 4 downtrend. It trades 43.4% below its 200-day average, which is falling.

How far is ARS Pharmaceuticals from its 52-week high?

ARS Pharmaceuticals closed at $4.32 on Oct 22, 2026, 66.9% below its 52-week high of $13.06. Its 52-week low is $3.93.

How has ARS Pharmaceuticals performed over the past year?

As of Oct 22, 2026, ARS Pharmaceuticals is down 56.4% over the past year and down 62.4% so far in 2026.

Which sector and industry is ARS Pharmaceuticals in?

ARS Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.